Zepteon, Inc. is a privately held corporation founded in 2012 that has developed a first in class chromatography resin, Glycap-3A, capable of separating antibodies with specific sugar structures (nonfucosylated) that are more potent against viruses and cancer. The affinity purification resin contains optimally immobilized FcgammaR3A receptors, leading to high antibody equilibrium binding capacities. Hyperimmune IgG is typically obtained from human donors who have been exposed to a virus and have generated virus specific antibodies. Literature indicates hyperimmune IgG would be far more potent against a range of viruses (Flu, MERS-CoV, Ebola, HPV, West Nile, CHIKV) using optimal IgG glycoforms and subclasses. In this talk, data showing that anti-viral plasma IgG fractionated using the Glycap-3A resin is far more potent against viral infection in mice will be presented. Zepteon resin is the only technology capable of simultaneously providing more potent IgG glycoforms and subclasses (IgG1 and IgG3) for the $1B USD hyperimmune IgG market. The resin can be used to rapidly obtain therapies after a viral outbreak. The method is faster than the generation, testing and scale up of monoclonal antibody therapies. The technology can enrich the most relevant IgGs from recently infected people to overcome viral strain mutation. In addition polyclonality provides multi-prong approach against viral escape. Zepteon is currently out-licensing the technology to IVIG and hyperimmune manufacturers for up-front, licensing and milestone payments

Zepteon: On demand antiviral antibody production

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.